(antihaemophilic factor)
One of the factors involved in the complex process of blood clotting. Freeze-dried Factor VIII fraction, prepared from human plasma, or recombinant human antihaemophilic factor VIII (octocog alfa or moroctocog alfa), prepared by genetic engineering techniques, is used for the prevention and treatment of bleeding in people with classical haemophilia (haemophilia A; see
haemostatic drugs). All preparations are available in a form for injection on
prescription only.
Side effects: include gastrointestinal upsets, alterations in taste, flushing, palpitation, breathlessness, cough, headache, dizziness, and allergic reactions, such as chills and fever.
Proprietary preparations: Alphanate; Fanhdi; Helixate NexGen; Kogenate (octocog alfa); Octanate; ReFacto AF (moroctocog alfa); 8Y;
Haemate P (combined with von Willebrand factor);
Optivate (combined with von Willebrand factor).